Search Results - M. A. Kolganova
-
1
PD-L1 as a Potential Target in Cancer Therapy (Review)
Published 2021-02-01Get full textIntroduction. Cancer is one of the most serious and common diseases with a high level of mortality. Due to this reason the searching of new directions and methods of cancer treatment is becoming more and more important with each passing year. Significant advances in cancer immunotherapy have been re...
Article -
2
Development and Validation of the ELISA Method for Neutralizing Anti-trastuzumab Antibodies Detection in Human Blood Serum
Published 2023-05-01Get full textIntroduction. Trastuzumab is the first known anti-HER2 agent, which revolutionized the treatment of one of the most common cancer types – breast cancer. Despite trastuzumab being approved long time ago, further improvement of related analytical methods remains relevant primarily due to the emergence...
Article -
3
PHARMACEUTICAL EDUCATION IN THE GREAT BRITAIN ON THE EXAMPLE UNIVERSITY OF BATH
Published 2019-01-01Get full textThe article shows the approaches to the educational process in preparation for the specialty "Pharmacy" in Russia and The United Kingdom, using the example of the University of Bath. Described features of the teaching of pharmacy, characteristic for the construction of training courses in...
Article -
4
A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd.,...
Published 2023-09-01Get full textIntroduction. Trastuzumab is the first drug based on the monoclonal antibodies’ technology targeted to the neu oncogene expression product discovered in the middle 80-s – human epidermal growth receptor, HER2. After being approved trastuzumab had become the drug of choice for combine therapy of meta...
Article -
5
Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer
Published 2020-05-01Get full textIntroduction. Neutropenia, which is an abnormally low concentration of neutrophils in the blood, is one of the common side effects in patients receiving radio- or chemotherapy. Neutropenia usually leads to higher risks of severe bacterial and fungal infections. Such medicines as colonystimulating fa...
Article -
6
Phase I Pharmacokinetics Study of Drug «COVID-globulin» (Specific Human Immunoglobulin Against COVID-19)
Published 2022-05-01Get full textIntroduction. Coronavirus infection is an acute viral disease with a predominant lesion of the upper respiratory tract caused by an RNA-containing virus of the Coronaviridae family. However, it is known that neutralizing antibodies play an important role in antiviral therapy because they effectively...
Article -
7
Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum
Published 2022-12-01Get full textIntroduction. One of the widely used specific anti-HER2 (human epidermal growth factor receptor 2) MAb drugs is trastuzumab. Trastuzumab is highly effective for malignant HER2 hyperexpression reduction, which results in HER2 oncogenicity decrease. As any other biotherapeutics trastuzumab can cause i...
Article -
8
A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Ru...
Published 2019-09-01Get full textIntroduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors. Phase I clinical trial was performed to assess pharmac...
Article